0
0
A recent study published in JAMA Dermatology has uncovered an unexpected benefit of GLP-1 weight-loss drugs like Ozempic and Wegovy beyond their primary use for diabetes and obesity: potential relief for hidradenitis suppurativa, a painful and chronic skin condition. However, experts emphasize the need for caution, as the findings come with important limitations and the medications are not yet approved for dermatologic use.
Hidradenitis suppurativa, also known as acne inversa, causes recurrent painful lumps under the skin, commonly in areas prone to friction such as the armpits and groin. It affects women approximately three times more often than men and is often difficult to treat. The condition is characterized by inflammation and scarring that can severely impact quality of life.
The recent French study tracked 66 hidradenitis suppurativa patients who were using GLP-1 drugs over an average of 18.5 months. Nearly 90 percent of participants also had diabetes, and their average body mass index (BMI) was 39.4, indicating obesity. Remarkably, by six months, over half of the patients reported relief from symptoms. By the end of the study, two-thirds experienced reduced severity of flare-ups and 60 percent reported less pain, suggesting a meaningful improvement in their skin condition.
Dr. Brendan Camp, a New York-based dermatologist not involved with the study, explained to Fox News Digital that the weight loss induced by GLP-1 drugs can reduce “mechanical friction” and “adipose-driven inflammation,” both of which exacerbate hidradenitis suppurativa. Additionally, these medications may have inherent anti-inflammatory properties that contribute to symptom relief, potentially aiding healing and reducing flare frequency.
Despite these encouraging findings, Dr. Camp and other experts caution that the study’s retrospective design and the specific patient population—mainly obese individuals with diabetes—limit how broadly the results can be applied. GLP-1 receptor agonists, while FDA-approved for diabetes and weight management, have not undergone rigorous clinical trials specifically for skin disorders. Off-label use for hidradenitis suppurativa should therefore be approached carefully, weighing possible side effects, costs, and the absence of definitive prospective trial evidence.
From a public health perspective, these findings may open new avenues for managing hidradenitis suppurativa, a condition that often resists conventional treatments and significantly diminishes patients’ well-being. However, it also highlights the importance of managing obesity and metabolic health, which appear intertwined with skin inflammation in these patients.
The study underscores the interconnectedness of chronic conditions and how medications aimed at one health issue can have unexpected benefits for others. Still, patients and healthcare providers should maintain realistic expectations and rely on multidisciplinary care involving dermatologists and endocrinologists to optimize treatment plans.
While further research, including randomized controlled trials, is essential to fully validate these results and establish safety and efficacy parameters, the current evidence offers a cautiously optimistic outlook on GLP-1 drugs as a dual-purpose therapy for weight management and hidradenitis suppurativa symptom relief.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
- https://health.economictimes.indiatimes.com/news/industry/weight-loss-drugs-are-trending-for-rapid-results-but-new-study-reveals-an-unexpected-benefit-with-a-catch/123574040?utm_source=top_story&utm_medium=homepage
